PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33294038-10	2020	Patients currently on hydroxychloroquine exhibited decreased levels of PCSK9 compared with those that were not taking hydroxychloroquine [beta coefficient -30 (95% CI -54 to -6) ng/ml, p = 0.015].	Hydroxychloroquine	22-40	proprotein convertase subtilisin/kexin type 9	Homo sapiens	71-76	
30603640-9	2018	Effects on PCSK9 concentrations by monotherapy with hydroxychloroquine (HCQ), which is thought having protective effects against AS in SLE, were investigated by follow-up analysis in 15 SLE patients.	Hydroxychloroquine	52-70	proprotein convertase subtilisin/kexin type 9	Homo sapiens	11-16	
30603640-9	2018	Effects on PCSK9 concentrations by monotherapy with hydroxychloroquine (HCQ), which is thought having protective effects against AS in SLE, were investigated by follow-up analysis in 15 SLE patients.	Hydroxychloroquine	72-75	proprotein convertase subtilisin/kexin type 9	Homo sapiens	11-16	
30603640-13	2018	Interestingly, monotherapy with HCQ for three months significantly reduced PCSK9 and CRP levels in inactive SLE patients.	Hydroxychloroquine	32-35	proprotein convertase subtilisin/kexin type 9	Homo sapiens	75-80	
30603640-15	2018	HCQ, which is thought having protective effects against AS in SLE, can effectively reduce PCSK9 levels in SLE patients.	Hydroxychloroquine	0-3	proprotein convertase subtilisin/kexin type 9	Homo sapiens	90-95